Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810166 | 0.96 | L3MBTL1 (0.48) | L3MBTL1USP30HCRTR1PRMT5CHEK2 | |
| SCHEMBL888992 | 0.88 | L3MBTL1 (0.59) | L3MBTL1USP30HCRTR1PRMT5CHEK2 | |
| SCHEMBL888999 | 0.84 | PRMT5 (0.40) | L3MBTL1HCRTR1PRMT5CHEK2HCRTR2 | |
| SCHEMBL889120 | 0.83 | CYP3A4 (0.52) | — | |
| SCHEMBL12771515 | 0.81 | OPRD1 (0.41) | USP30HCRTR1PRMT5CHEK2HCRTR2 | |
| SCHEMBL883274 | 0.80 | USP30 (0.43) | L3MBTL1USP30GPR119UCHL1 | |
| SCHEMBL883261 | 0.80 | USP30 (0.43) | L3MBTL1USP30GPR119UCHL1 | |
| SCHEMBL888977 | 0.80 | PRMT5 (0.43) | HCRTR1PRMT5CHEK2HCRTR2GPR119 | |
| SCHEMBL12810003 | 0.80 | L3MBTL1 (0.57) | L3MBTL1USP30PRMT5CHEK2GPR119 | |
| SCHEMBL889122 | 0.80 | PRMT5 (0.48) | HCRTR1PRMT5CHEK2HCRTR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | L3MBTL1 2822/4885USP30 2645/4885HCRTR1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.